🌍September 30, 2026·2d agodiscoveryTier 3 · Aggregated media

INGENIA files for U.S. Phase 1/2a trials for CKD candidate ‘IGT-303,’ accelerates licensing-out discussions

Publisher

더

더바이오

Global

This page provides publisher metadata, and related coverage to support discovery before sending readers to the attributed publisher through Google News.

Open via Google News

At a glance

Publisher: 더바이오
Region: Global
Scope: discovery
Published: September 30, 2026
Language: EN

Publisher context, original article off-platform

This page presents the title, publisher metadata, and related coverage. The publisher did not provide a public summary in this feed. Full-text reading stays on the publisher's original site.

Source route

Continue on news.google.com

This record currently routes through Google News. Confirm important claims against the publisher or a primary record.

Source: 더바이오

Scope: discovery

Evidence: Tier 3 · Aggregated media

Open Google News route

Related coverage

More related coverage

Pharmaceutical Technology/9h ago

Varda pockets $251m to back space-based pharma processing mission

PR Newswire/9h ago

Cardinal Health Enters into Binding Letter of Intent to Extend Pharmaceutical Distribution Agreements with CVS Health

STAT/9h ago

Invivyd’s pursuit of a Covid vaccine alternative gets a lift, but an FDA hurdle may await